Surrogate markers of outcome in PSVD: do’s and don’ts - Paris PSVD Meeting

Value of the Information & Strength of the Argument

The presentation provides valuable insights into the selection and validation of surrogate markers in PSVD, a rare liver disease. The argumentation is grounded in clinical data, including a multicenter cohort study, and incorporates expert consensus. The speaker critically evaluates potential surrogates, discussing their strengths and limitations, such as the impact of anesthesia on PPG measurements and the prognostic value of LSM/SSM. The discussion with the audience adds depth, addressing concerns about the validity of stiffness changes as surrogates and the need for robust trial designs. The value lies in its practical guidance for researchers and clinicians, though the lack of detailed statistical data and references limits its standalone scientific rigor.

Scientific Rigor, Source Quality, Title Accuracy

The presentation demonstrates scientific rigor through the use of clinical data and reference to published studies (e.g., Valdik study, Baveno guidelines). However, specific citations are not provided in the video, and the reliance on expert opinion and consensus is evident. The title accurately reflects the content, focusing on surrogate markers with practical recommendations. The discussion includes critical feedback from peers, enhancing the credibility of the content. The absence of detailed methodology and peer-reviewed references in the video itself is a limitation, but the context of a scientific meeting suggests a high level of expertise.

The title accurately reflects the content, which focuses on surrogate markers in PSVD, including practical recommendations and caveats.

8/10

Presentation by a recognized expert in hepatology, based on clinical data and consensus discussions, but limited by the absence of detailed methodological descriptions and peer-reviewed references in the video.

Markers derived by PSI from the transcript: the creator did not define chapters.

• 02:00Introduction to the importance of surrogate markers in PSVD trials.
• 05:00Proposal of surrogate markers for patients without portal hypertension signs.
• 08:00Discussion on portal pressure gradient as a surrogate, including anesthesia effects.
• 10:00Presentation of liver and spleen stiffness data from Valdik study.
• 12:00Validation of stiffness thresholds in multicenter cohort.
• 14:00Debate on portal vein thrombosis as surrogate vs hard endpoint.
• 16:00Discussion on platelet count and its lack of association with outcomes.
• 18:00Audience questions on LSM/SSM as surrogates and need for intervention studies.
• 20:00Considerations for future studies and validation of surrogates.

• Baveno VII guidelines — Referenced for classification of portal hypertension.
• Valdik study — Multicenter cohort validating LSM/SSM thresholds.
• Matameas study — Study of 587 patients showing platelet count not associated with outcomes.

• Baveno VII consensus — Supports use of LSM and SSM in portal hypertension.

• Platelet count as surrogate — Some panel members suggested platelet count, but data from Matameas study showed no association.